Discover 701 paid clinical trials in Killeen, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 701
Sacituzumab Govitecan in Recurrent Glioblastoma
for
Recurrent Glioblastoma
Location: Austin TX, San Antonio TX, Cleveland OH
Sponsor: The University of Texas Health Science Center at San Antonio
Sex: All
Age: 18+
Code: NCT04559230
Phase 2, Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
for
Untreated, Unresectable, or Metastatic Colorectal Cancer
Location: Austin TX, Arlington TX, San Antonio TX, Houston TX,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07221357
Phase 2, Phase 3, Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
for
Acute Myeloid Leukemia (AML)
Location: Austin TX, San Antonio TX, Dallas TX, Houston TX,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT07007312
Phase 3, Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
for
Urothelial Cancer, Urinary Bladder Neoplasms
Location: Austin TX, Tyler TX, Little Rock AR, Columbia MO,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07566156
Phase 3, Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Location: Austin TX, Arlington TX, San Antonio TX, Houston TX,
Sponsor: UroGen Pharma Ltd.
Sex: All
Age: 18+
Code: NCT06774131
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Location: Austin TX, West Columbia SC, Fort Lauderdale FL,
Sponsor: Ocular Therapeutix, Inc.
Sex: All
Age: 50+
Code: NCT07516132
Phase 3, Recruiting
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration